4.10
Avalo Therapeutics Inc Aktie (AVTX) Neueste Nachrichten
Avalo Therapeutics Signs New Sales Agreement - TipRanks
Avalo Therapeutics Highlights AVTX-009 Potential in HS Market - TipRanks
Northern Trust Corp Invests $168,000 in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded at HC Wainwright - Defense World
H.C. Wainwright upgrades Avalo Therapeutics stock to buy - Investing.com
Avalo Therapeutics assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright upgrades Avalo Therapeutics stock to buy By Investing.com - Investing.com South Africa
AVTX: Avalo Therapeutics Receives Buy Rating with $15 Target Pri - GuruFocus
Avalo Therapeutics (AVTX) Receives Buy Rating from H.C. Wainwright | AVTX Stock News - GuruFocus
Cardax (OTCMKTS:CDXI) and Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Analysis - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Avalo Therapeutics to Participate in Upcoming Investor Conferenc - GuruFocus
Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Bought by Tower Research Capital LLC TRC - Defense World
Strong Cash Position Secures AVTX Through 2027 | AVTX Stock News - GuruFocus
Avalo Therapeutics Reports Improved Financial Performance - TipRanks
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire
Avalo Therapeutics reports Q1 EPS ($1.25) vs. ($141.14) last year - TipRanks
Avalo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
AVTX Advances Phase 2 LOTUS Trial, Targets 2026 Data | AVTX Stoc - GuruFocus
AVALO THERAPEUTICS Earnings Results: $AVTX Reports Quarterly Earnings - Nasdaq
Avalo Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Avalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa - Nasdaq
Avalo Therapeutics, Inc. SEC 10-Q Report - TradingView
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire Inc.
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Avalo Therapeutics Updates on AVTX-009 and LOTUS Trial - TipRanks
15,323 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Acquired by Marshall Wace LLP - Defense World
When the Price of (AVTX) Talks, People Listen - news.stocktradersdaily.com
Avalo Therapeutics Enters $75 Million Sales Agreement With TD Cowen For Common Stock Offering - marketscreener.com
Geode Capital Management LLC Increases Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - The Manila Times
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 20.3% in March - Defense World
60,000 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Purchased by Bank of Montreal Can - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $33.00 Average PT from Brokerages - Defense World
Avalo Therapeutics (AVTX) Sees New Options Listings for April | AVTX Stock News - GuruFocus
Seven new option listings and one option delisting on April 16th - TipRanks
Avalo Therapeutics Reports 2024 Financial Results - TipRanks
Advanced Cancer Pain Management Therapeutics Market Size in 7MM - openPR.com
(AVTX) On The My Stocks Page - news.stocktradersdaily.com
AVTX stock touches 52-week low at $5.98 amid market challenges - Investing.com Australia
AVTX stock touches 52-week low at $5.98 amid market challenges By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Stifel Nicolaus - MarketBeat
Avalo Therapeutics (AVTX) to Release Earnings on Friday - Defense World
Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics names new Chairman amid growth phase By Investing.com - Investing.com South Africa
Avalo Therapeutics Names Michael Heffernan as Board Chairman - MarketScreener
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board - MarketScreener
Avalo Therapeutics names new Chairman amid growth phase - Investing.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):